Newton, Massachusetts, December 6, 2023- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the..
Relevance: 36.01345